Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.

Arenas-Gamboa AM, Rice-Ficht AC, Fan Y, Kahl-McDonagh MM, Ficht TA.

Clin Vaccine Immunol. 2012 Feb;19(2):249-60. doi: 10.1128/CVI.05321-11. Epub 2011 Dec 14.

2.

Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Arenas-Gamboa AM, Rice-Ficht AC, Kahl-McDonagh MM, Ficht TA.

Infect Immun. 2011 Sep;79(9):3653-8. doi: 10.1128/IAI.05330-11. Epub 2011 Jun 27. Erratum in: Infect Immun. 2011 Dec;79(12):5040.

3.

Polymeric particles in vaccine delivery.

Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA.

Curr Opin Microbiol. 2010 Feb;13(1):106-12. doi: 10.1016/j.mib.2009.12.001. Epub 2010 Jan 14. Review.

PMID:
20079678
4.

Brucellosis: the case for live, attenuated vaccines.

Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC.

Vaccine. 2009 Nov 5;27 Suppl 4:D40-3. doi: 10.1016/j.vaccine.2009.08.058. Review.

5.

The Brucella abortus S19 DeltavjbR live vaccine candidate is safer than S19 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle.

Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht AC.

Infect Immun. 2009 Feb;77(2):877-84. doi: 10.1128/IAI.01017-08. Epub 2008 Dec 1.

6.

Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge.

Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC.

Infect Immun. 2008 Jun;76(6):2448-55. doi: 10.1128/IAI.00767-07. Epub 2008 Mar 24.

7.

Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.

Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA.

Infect Immun. 2007 Oct;75(10):4923-32. Epub 2007 Jul 30.

9.

Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.

Kahl-McDonagh MM, Elzer PH, Hagius SD, Walker JV, Perry QL, Seabury CM, den Hartigh AB, Tsolis RM, Adams LG, Davis DS, Ficht TA.

Vaccine. 2006 Jun 12;24(24):5169-77. Epub 2006 Apr 27.

PMID:
16697090

Supplemental Content

Loading ...
Support Center